Darolutamide Patent Expiration
Darolutamide is Used for treating non-metastatic castration-resistant prostate cancer. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Darolutamide Patents
Given below is the list of patents protecting Darolutamide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nubeqa | US12329742 | Pharmaceutical composition of darolutamide | May 14, 2042 | Bayer Healthcare |
| Nubeqa | US11168058 | Manufacture of a crystalline pharmaceutical product | Feb 27, 2038 | Bayer Healthcare |
| Nubeqa | US10010530 | Carboxamide derivative and its diastereomers in stable crystalline form | Jan 28, 2036 | Bayer Healthcare |
| Nubeqa | US10383853 | Carboxamide derivative and its diastereomers in stable crystalline form | Jan 28, 2036 | Bayer Healthcare |
| Nubeqa | US10835515 | Carboxamide derivative and its diastereomers in stable crystalline form | Jan 28, 2036 | Bayer Healthcare |
| Nubeqa | US8975254 | Androgen receptor modulating compounds | Mar 25, 2033 | Bayer Healthcare |
| Nubeqa | US10711013 | Androgen receptor modulating compounds | Oct 27, 2030 | Bayer Healthcare |
| Nubeqa | US11046713 | Androgen receptor modulating compounds | Oct 27, 2030 | Bayer Healthcare |
| Nubeqa | US9657003 | Androgen receptor modulating compounds | Oct 27, 2030 | Bayer Healthcare |
Darolutamide's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List